Phase II and Coagulation Study of rhuMAb-VEGF With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma.

Trial Profile

Phase II and Coagulation Study of rhuMAb-VEGF With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2013

At a glance

  • Drugs Bevacizumab; Docetaxel
  • Indications Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 May 2010 Results published in American Journal of Clinical Oncology.
    • 16 Feb 2010 Actual end date changed from 1 Nov 2008 to 1 Apr 2009 as reported by ClinicalTrials.gov.
    • 10 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top